Price Alert

Metsera Inc. (MTSR)

NASDAQ: MTSR · Real-Time Price · USD

52.52

-0.45 (-0.85%)

At close: Oct 14, 2025, 3:59 PM

52.56

0.08%

After-hours: Oct 14, 2025, 07:08 PM EDT

-0.85% (1D)

Bid	37.8
Market Cap	5.52B
Revenue (ttm)	n/a
Net Income (ttm)	-307.82M
EPS (ttm)	-2.93
PE Ratio (ttm)	-17.92
Forward PE	-14.52
Analyst	Buy
Dividends	n/a

Ask	67.52
Volume	957,869
Avg. Volume (20D)	2,116,621
Open	52.59
Previous Close	52.97
Day's Range	52.40 - 53.23
52-Week Range	12.30 - 54.47
Beta	1.63
Ex-Dividend Date	n/a

About MTSR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MTSR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MTSR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

+60.8%

Metsera shares are trading higher on reports that ... Unlock content with Pro Subscription

2 months ago

-5.73%

Metsera shares are trading lower after the company reported worse-than-expected Q2 EPS results.

News

1 day ago · proactiveinvestors.co.uk

IP Group: Metsera deal highlights hidden value, say analysts

Sometimes value can be hidden in plain sight. Berenberg thinks that is the case with IP Group PLC (LSE:IPO), the London-listed investor in university spin-outs, where it sees a “significant" opportuni...

2 days ago · proactiveinvestors.co.uk

IP Group shares climb 9% on potential royalties from Pfizer's $7.3bn Metsera deal

Shares in IP Group PLC (LSE:IPO) rose 9% on Monday after investors welcomed the potential for future royalty income from Metsera, a biotech company that Pfizer has agreed to acquire for up to $7.3 bil...

2 weeks ago · cnbc.com

Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug

Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.

2 weeks ago · barrons.com

Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.

Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.

2 weeks ago · reuters.com

Metsera's obesity drug shows promising weight loss in mid-stage trials

Metsera said on Monday that its experimental obesity drug showed significant weight loss and favorable tolerability in mid-stage studies.

3 weeks ago · zacks.com

Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?

Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).

3 weeks ago · businesswire.com

METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale Met...

3 weeks ago · proactiveinvestors.co.uk

Pfizer's Metsera buy raises competitive heat for Novo Nordisk

UBS has warned that Pfizer Inc's (NYSE:PFE, ETR:PFE) $7.3 billion acquisition of Metsera will sharpen competition for Novo Nordisk (NYSE:NVO) in the fast-growing obesity drug market, particularly towa...

3 weeks ago · fastcompany.com

Pfizer bets $7.3 billion on obesity drugs with Metsera buy

Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications fo...

3 weeks ago · youtube.com

BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity

Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'The Exchange' to discuss Pfizer's obesity drug prospects, competitors and much more.

Load More News